Table 4.
Final population pharmacodynamics model parameter estimates
| Parameter | Population estimate | Bootstrapa | |
|---|---|---|---|
| Median | 95% CI | ||
| Emax, d−1 | 18.8 | 18.8 | 14.9–22.3 |
| EC50, ng/mL | 82.7 | 82.7 | 63.7–87.8 |
| Life span [Λ], d | 2.64 FIX | ||
| IIV | |||
| ηEmax, %CV | 41.0 | 41.0 | 36.2–51.4 |
| ηEC50, %CV | 40.6 | 40.6 | 37.2–55.0 |
| ηΛ, %CV | 50.4 | 50.4 | 48.1–69.4 |
| Residual variability | |||
| Proportional error, %CV | 76.6 | 76.6 | 64.6–84.6 |
CI, confidence interval; CV, coefficient of variation; EC50, half‐maximal effective concentration; Emax, maximal rate of eosinophil destruction by benralizumab; IIV, interindividual variability.
a
Based on 950 runs with parameter significant digits ≥2 (of 1,000 bootstrap runs).